HIPEC for colorectal peritoneal metastases
Mené en France entre 2008 et 2014 sur 265 patients atteints d'un cancer colorectal et présentant des métastases péritonéales (âge : 18-70 ans ; durée médiane de suivi : 64 mois), cet essai randomisé multicentrique de phase 3 évalue l'intérêt, du point de vue de la survie globale, d'ajouter une chimiothérapie intrapéritonéale hyperthermique à une chirurgie cytoréductive
The treatment of patients with metastatic colorectal cancer has changed profoundly over the past 25 years. In 1995, fluorouracil was the only active chemotherapy available for the disease, and long-term survival (ie, for at least 5 years) was rarely achieved with chemotherapy alone. Only patients with surgically resectable liver and lung metastases had a reasonable chance of long-term survival. Since then, more chemotherapeutic drugs have been approved, and median survival has increased to 2–3 years (from around 6–12 months), with 20–25% of patients surviving for at least 5 years.
The Lancet Oncology , commentaire, 2020